title: Central serous chorioretinopathy associated with administration of sympathomimetic agents.
abstract: OBJECTIVE
  To report central serous chorioretinopathy associated with excessive use of compounds with sympathomimetic activity.
  
  
  METHODS
  Observational case series.
  
  
  METHODS
  Four patients presented with clinical and fluorescein angiographic evidence of central serous chorioretinopathy. All patients expressed a concomitant psychogenic stress and high-dose ingestion of pseudoephedrine, oxymetazoline, or 3,4-methylenedioxymethamphetamine, all of which possess sympathomimetic properties.
  
  
  RESULTS
  In all cases, resolution of central serous chorioretinopathy coincided with cessation of the medication.
  
  
  CONCLUSIONS
  Patients afflicted with central serous chorioretinopathy should be notified about its possible association with sympathomimetic medications.
authors.affiliation: Retina Institute of Illinois, Niles, Illinois 60714, USA. johnmichael@aol.com
authors.forename: John C
authors.initials: JC
authors.lastname: Michael
authors.forename: John
authors.initials: J
authors.lastname: Pak
authors.forename: Jose
authors.initials: J
authors.lastname: Pulido
authors.forename: Guillermo
authors.initials: G
authors.lastname: de Venecia
mesh_terms: D000328:Adult; D015862:Choroid Diseases / Q000139:chemically induced* / Q000175:diagnosis; D004809:Ephedrine / Q000009:adverse effects; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D008297:Male; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000009:adverse effects; D009887:Ophthalmoscopy; D010109:Oxymetazoline / Q000009:adverse effects; D012164:Retinal Diseases / Q000139:chemically induced* / Q000175:diagnosis; D013566:Sympathomimetics / Q000009:adverse effects*; D014792:Visual Acuity
chemical_list: D013566:Sympathomimetics; D010109:Oxymetazoline; D004809:Ephedrine; D018817:N-Methyl-3,4-methylenedioxyamphetamine